GlassScriptPhysician profile
Mackenzie Bruce Dickinson
NPI 1003301557
$1,344.25
in general payments reported to CMS, 2019-2025
31 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.48 · 2020: $143 · 2021: $286 · 2022: $637 · 2023: $73.19 · 2024: $51.38 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $345.53 | 2020-2024 | Vraylar |
| Novo Nordisk INC | $130.77 | 2021-2022 | |
| Pfizer INC. | $60.43 | 2019-2023 | |
| Amgen INC. | $59.91 | 2022-2025 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $59.02 | 2022 | |
| Glaxosmithkline, LLC. | $55.08 | 2022-2025 | Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $53.57 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $52.89 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $40.59 | 2021-2022 | |
| Lilly USA, LLC | $40.13 | 2022 | |
| Daiichi Sankyo INC. | $36.88 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $34.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.11 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $33.93 | 2021-2022 | |
| Bardy Diagnostics, INC. | $30.16 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.21 | 2022 | |
| Viatris Specialty LLC | $26.04 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $21.36 | 2022 | |
| Abbott Laboratories | $19.58 | 2025 | Freestyle Libre 3 |
| Myovant Sciences INC. | $19.44 | 2022 | |
| Boston Scientific Corporation | $18.46 | 2024 | |
| Alkermes, INC. | $18.23 | 2021 | |
| Exact Sciences Corporation | $17.24 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $15.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.71 | 2021 | |
| Allergan, INC. | $13.69 | 2020 | |
| Alvogen INC | $13.59 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.44 | 2021 | |
| Lundbeck LLC | $12.09 | 2021 | |
| Mylan Pharmaceuticals INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Dickinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.